AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 12 min read$NVCT

Mosseri Marlio Charles purchased $916K of NVCT (indirect holdings)

Mosseri Marlio Charles purchased 50,000 indirectly-held shares of Nuvectis Pharma, Inc. (NVCT) at $18.32 ($0.92M total) on 2026-06-30.

Original reporting
SEC EDGAR · Mosseri Marlio Charles
Published Jul 1, 2026, 5:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 5:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NVCT
Bullish
low confidence
Mentioned
$NVCT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVCTBullishLow
01

Why it matters

The newest fact is the disclosed open-market purchase amount, price, and post-transaction share count; it may slightly influence sentiment but does not change the company’s fundamentals in the text.

02

Market read

Traders may monitor for follow-on insider activity or corroborating catalysts, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

For micro/small-cap biotech, price action may be dominated by upcoming catalysts (trial readouts, financing, FDA/regulatory updates) rather than insider transactions.

Relevance 6/10Novelty 6/10Timing: Filed 2026-07-01 after-hours/late session; reflects 2026-06-30 purchase.

Background

The article is an SEC Form 4 insider transaction disclosure for Nuvectis Pharma, Inc. (NVCT).

Company-level read

Ticker impact

$NVCTBullishLow confidence
Context

Form 4 shows 10% owner Mosseri Marlio Charles bought 50,000 NVCT shares on 2026-06-30 for $916,000 at $18.32.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven and should fade without follow-on news.

Evidence & confidence

The filing is a primary disclosure, but it lacks new operational/clinical/regulatory information and is an indirect holding with no 10b5-1 plan.

Market effects

Sector

No direct sector read-across; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Indirect holdings and absence of a 10b5-1 plan don’t guarantee conviction; buying could be tax/estate or liquidity-related rather than a forward-looking signal.

Key entities

  • issuer
    Nuvectis Pharma, Inc.

    Subject of the Form 4 insider transaction disclosure (NVCT).

  • insider
    Mosseri Marlio Charles

    10% owner reporting an indirect open-market purchase of NVCT shares.

Read at source← All news

Related articles

AUG 4
$NVCTMedAI 9/10

Nuvectis Pharma, Inc.: Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma (NASDAQ: NVCT) reported Q2 2026 results and said it completed in-licensing ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco. Ciprocopan received China marketing approval in July 2026 for PNH patients not previously treated with complement inhibitors. The company raised $115M gross in a July follow-on offering, extending cash runway into 1H 2029. Cash was $22.2M at June 30, 2026; net loss was $7.0M.

finanznachrichten.de6 min
AUG 4
$NVCTMed

Nuvectis Pharma, Inc. (NVCT): Results of Operations and Financial Condition

Nuvectis Pharma, Inc. (NVCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights · Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical G

SEC EDGAR 8-K5 min
JUL 14
$NVCTMedAI 8/10

Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Nuvectis Pharma (NVCT) said it licensed worldwide rights outside China to NXP100 and NXP200 from Haisco Pharmaceutical Group for $40M upfront plus up to $1.42B in milestones. NVCT cites Phase 3 results for NXP100 in PNH versus eculizumab: 59.5% vs 8.3% transfusion-free normal hemoglobin. Two China NMPA applications are under review, with decisions expected late 2026 to early 2027.

finanznachrichten.de5 min
JUN 30
$NVCTMedAI 8/10

Nuvectis Pharma Stock Falls 30%

Nuvectis Pharma, Inc. (NVCT) shares fell about 30% on Tuesday. The drop follows the company’s announcement of a 5 million-share offering priced at $20.00 per share, targeting about $100 million in gross proceeds, according to the report. NVCT was around $19.90, down from a prior close of $28.53 on Nasdaq.

rttnews.com2 min
JUN 24
$NVCTMedAI 8/10

Haisco and Nuvectis sign licensing deal for two drugs

Haisco and Nuvectis signed a licensing deal covering Haisco’s drug candidates HSK42360 and HSK39297. Nuvectis received worldwide rights outside specified Asian territories to develop, manufacture and commercialise. Haisco will get $40m upfront/near-term, plus milestones up to $1.4bn and tiered royalties. Milestones may include cash and common stock (equity capped <40%); financing conditions apply.

pharmaceutical-business-review.com3 min